Reported Earnings • Apr 24
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: CN¥1.75 (up from CN¥1.32 in FY 2024). Revenue: CN¥1.32b (up 20% from FY 2024). Net income: CN¥151.7m (up 29% from FY 2024). Profit margin: 12% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 16% per year. Annuncio • Apr 23
Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026 Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026, at 09:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China Annuncio • Mar 30
Bide Pharmatech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Bide Pharmatech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 New Risk • Mar 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (197% cash payout ratio). Share price has been volatile over the past 3 months (8.3% average weekly change). Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥48.50, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total loss to shareholders of 45% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥21.89 per share. Reported Earnings • Mar 05
Full year 2025 earnings released: EPS: CN¥1.75 (vs CN¥1.32 in FY 2024) Full year 2025 results: EPS: CN¥1.75 (up from CN¥1.32 in FY 2024). Revenue: CN¥1.32b (up 20% from FY 2024). Net income: CN¥152.2m (up 30% from FY 2024). Profit margin: 12% (in line with FY 2024). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Jan 30
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥59.86, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total loss to shareholders of 31% over the past three years. Annuncio • Dec 26
Bide Pharmatech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 Major Estimate Revision • Nov 20
Consensus EPS estimates increase by 10% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from CN¥1.60 to CN¥1.77. Revenue forecast steady at CN¥1.34b. Net income forecast to grow 31% next year vs 31% growth forecast for Pharmaceuticals industry in China. Consensus price target of CN¥83.00 unchanged from last update. Share price was steady at CN¥76.14 over the past week. Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.53 (vs CN¥0.36 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.53 (up from CN¥0.36 in 3Q 2024). Revenue: CN¥351.6m (up 26% from 3Q 2024). Net income: CN¥46.3m (up 45% from 3Q 2024). Profit margin: 13% (up from 12% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Oct 24
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥76.99, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 33% over the past three years. Annuncio • Sep 30
Bide Pharmatech Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Bide Pharmatech Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥74.73, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 159% over the past year. Reported Earnings • Aug 25
Second quarter 2025 earnings released: EPS: CN¥0.51 (vs CN¥0.29 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.51 (up from CN¥0.29 in 2Q 2024). Revenue: CN¥331.2m (up 23% from 2Q 2024). Net income: CN¥42.7m (up 66% from 2Q 2024). Profit margin: 13% (up from 9.6% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Annuncio • Jun 30
Bide Pharmatech Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025 Bide Pharmatech Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025 Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥58.02, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 100% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.75 per share. Board Change • Jun 25
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. R&D Director and Supervisor Ronghao Li is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.34 (vs CN¥0.29 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.34 (up from CN¥0.29 in 1Q 2024). Revenue: CN¥296.4m (up 13% from 1Q 2024). Net income: CN¥30.7m (up 18% from 1Q 2024). Profit margin: 10% (in line with 1Q 2024). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Annuncio • Apr 24
Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025 Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to CN¥37.81, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 14% over the past year. Annuncio • Mar 28
Bide Pharmatech Co., Ltd. to Report Q1, 2025 Results on Apr 24, 2025 Bide Pharmatech Co., Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025 Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥59.26, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total returns to shareholders of 46% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥107 per share. Annuncio • Feb 10
Bide Pharmatech Co., Ltd. (SHSE:688073) announces an Equity Buyback for CNY 100 million worth of its shares. Bide Pharmatech Co., Ltd. (SHSE:688073) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 72.30 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds and special loans. The program will be valid for 6 months. Price Target Changed • Feb 05
Price target increased by 25% to CN¥50.00 Up from CN¥40.00, the current price target is provided by 1 analyst. New target price is 12% above last closing price of CN¥44.51. Stock is up 21% over the past year. The company is forecast to post earnings per share of CN¥1.35 for next year compared to CN¥1.21 last year. Board Change • Feb 05
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). R&D Director and Supervisor Ronghao Li is the most experienced director on the board, commencing their role in 2020. Independent Director Hong Meng was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Annuncio • Jan 22
Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd. Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd. on January 21, 2025. The consideration consists of common equity of Bide Pharmatech Co., Ltd. to be issued for common equity of Zhuhai Weibo Investment Co., Ltd. As part of consideration, an undisclosed value is paid towards common equity of Zhuhai Weibo Investment Co., Ltd. Annuncio • Dec 27
Bide Pharmatech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 24, 2025 Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 24, 2025 New Risk • Dec 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 101% Cash payout ratio: 141% Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Profit margins are more than 30% lower than last year (7.3% net profit margin). Price Target Changed • Dec 04
Price target increased by 25% to CN¥50.00 Up from CN¥40.00, the current price target is provided by 1 analyst. New target price is 17% above last closing price of CN¥42.68. Stock is down 28% over the past year. The company is forecast to post earnings per share of CN¥1.35 for next year compared to CN¥1.21 last year. Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥42.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 35% over the past year. Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.33 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.36 (up from CN¥0.33 in 3Q 2023). Revenue: CN¥279.2m (down 1.1% from 3Q 2023). Net income: CN¥32.0m (up 8.2% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥33.16, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total loss to shareholders of 51% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.54 per share. Buy Or Sell Opportunity • Oct 10
Now 21% undervalued Over the last 90 days, the stock has risen 11% to CN¥34.50. The fair value is estimated to be CN¥43.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last year. Earnings per share has declined by 63%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 108% in the next 2 years. Annuncio • Sep 30
Bide Pharmatech Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Bide Pharmatech Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to CN¥37.43, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 46% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.54 per share. Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.51 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.51 in 2Q 2023). Revenue: CN¥269.5m (flat on 2Q 2023). Net income: CN¥25.8m (down 45% from 2Q 2023). Profit margin: 9.6% (down from 17% in 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Annuncio • Jun 29
Bide Pharmatech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Bide Pharmatech Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Annuncio • May 15
Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024 Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.41 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.41 in 1Q 2023). Revenue: CN¥262.7m (up 4.0% from 1Q 2023). Net income: CN¥26.1m (down 29% from 1Q 2023). Profit margin: 9.9% (down from 15% in 1Q 2023). Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Annuncio • Mar 29
Bide Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Bide Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥36.16, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 60% over the past year. Reported Earnings • Feb 03
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥1.24 (down from CN¥1.98 in FY 2022). Revenue: CN¥1.09b (up 31% from FY 2022). Net income: CN¥113.0m (down 23% from FY 2022). Profit margin: 10% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥40.47, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total loss to shareholders of 55% over the past year. Annuncio • Dec 30
Bide Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥72.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥59.09, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 20x in the Pharmaceuticals industry in China. New Risk • Aug 31
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 38% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (38% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows. Reported Earnings • Aug 05
Second quarter 2023 earnings released: EPS: CN¥0.51 (vs CN¥0.49 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.51 (up from CN¥0.49 in 2Q 2022). Revenue: CN¥270.2m (up 41% from 2Q 2022). Net income: CN¥46.9m (up 39% from 2Q 2022). Profit margin: 17% (in line with 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥79.52, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 20x in the Pharmaceuticals industry in China. New Risk • Jul 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). High level of non-cash earnings (22% accrual ratio). Minor Risk Dividend is not well covered by cash flows (287% cash payout ratio). Valuation Update With 7 Day Price Move • May 30
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥78.30, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Reported Earnings • Apr 24
First quarter 2023 earnings released: EPS: CN¥0.57 (vs CN¥0.61 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.57. Revenue: CN¥252.5m (up 37% from 1Q 2022). Net income: CN¥36.9m (up 25% from 1Q 2022). Profit margin: 15% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥148, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 24x in the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥152, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Reported Earnings • Jan 17
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: CN¥2.76 (up from CN¥2.04 in FY 2021). Revenue: CN¥833.8m (up 38% from FY 2021). Net income: CN¥145.8m (up 49% from FY 2021). Profit margin: 18% (up from 16% in FY 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 30%. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥97.08, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.63 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.79 (up from CN¥0.63 in 3Q 2021). Revenue: CN¥219.9m (up 22% from 3Q 2021). Net income: CN¥38.8m (up 26% from 3Q 2021). Profit margin: 18% (in line with 3Q 2021).